title: A review of adverse events caused by immune checkpoint inhibitors.
abstract: There has been no effective therapy in the unresectable melanoma for more than 40 years. Anti-PD-1 antibody and anti-CTLA-4 antibody have totally changed the situation. They have clearly shown the survival benefits of the patients with metastatic melanoma. However, immune checkpoint inhibitors sometimes induce various kinds of immune-related adverse events (irAEs). It is very important for the clinicians to know the reported cases of irAEs and to keep in mind the symptoms of irAEs for the early detection. This review describes the previously reported irAEs and adequate managements for irAEs induced by immune checkpoint inhibitors.
authors.affiliation: Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fukushima
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003092:Colitis / Q000139:chemically induced; D004700:Endocrine System Diseases / Q000139:chemically induced; D006801:Humans; D000074324:Ipilimumab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy; D026901:Membrane Transport Proteins / Q000276:immunology*; D009157:Myasthenia Gravis / Q000139:chemically induced; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*; D012871:Skin Diseases / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D026901:Membrane Transport Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C583905:SLC44A4 protein, human; D000077594:Nivolumab